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The 2009 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hyperten-
sion (PAH) but also some aspects of pulmonary hypertension (PH) in chronic lung disease. These guidelines
point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antago-
nists and phosphodiesterase type-5 inhibitors) have not been suﬃciently investigated in other forms of PH.
Therefore, the use of these drugs in patients with chronic lung disease and PH is not recommended. This
recommendation, however, is not always in agreement with medical needs as physicians feel sometimes in-
clined to also treat other forms of pulmonary hypertension which may affect the quality of life and survival
of these patients in a similar manner as in PAH. In June 2010, a consensus conference was held in Cologne,
Germany, to discuss open and controversial issues surrounding the practical implementation of the European
Guidelines. The conference was sponsored by the German Society of Cardiology, the German Society of Respi-
ratory Medicine and the German Society of Pediatric Cardiology (DGK, DGP and DGPK). To this end, a number
of working groups were initiated, one of which was speciﬁcally dedicated to the diagnosis and treatment of
PH due to chronic lung disease. This manuscript describes in detail the results and recommendations of this
working group which were last updated in October 2011.
© 2011 Elsevier Ireland Ltd. All rights reserved.
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ference on pulmonary hypertension are described that was held
in June 2010 in Cologne, Germany, and was organized by the
pulmonary hypertension (PH) working groups of the German Soci-
eties of Cardiology (Deutsche Gesellschaft für Kardiologie, DGK)
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and Respiratory Medicine (Deutsche Gesellschaft für Pneumologie,
DGP) and the German Society of Pediatric Cardiology (Deutsche
Gesellschaft für Pädiatrische Kardiologie, DGPK). This conference
addressed practical issues surrounding the implementation of the
European Guidelines for diagnosis and therapy of pulmonary hy-
pertension in Germany. To this end, a number of working groups
were initiated, one of which was speciﬁcally dedicated to PH due
to chronic lung disease. The authors were members of this working
group, and the recommendations were updated in October 2011.
Below, the corresponding sections of the European Guidelines are
summarized [1–3] whereby comments and additions appear in
italics. The information on class of recommendation and level of
evidence correspond to the tables listed in the preamble of this
supplement.
1. Introduction
The diagnosis and treatment of patients with pulmonary hy-
pertension due to chronic lung disease according to group 3 of
the current classiﬁcation (Table 1) are discussed only brieﬂy in the
European guidelines. This article addresses these issues in detail
and in some sections falls back on the recommendations of the 4th
World Symposium on Pulmonary Hypertension that took place in
2008 in Dana Point, California [4]. Focus is on pulmonary hyper-
tension in chronic obstructive or interstitial lung disease. The other
types of pulmonary hypertension associated with lung disease that
are listed in Table 1, cannot be discussed in detail. This applies to
the diseases listed for group 3 as well as for speciﬁc diseases from
group 5 such as sarcoidosis or pulmonary Langerhans cell granulo-
matosis. The statements throughout this article can be applied in
principle to all diseases named in groups 3 and 5.
2. Hemodynamic deﬁnition of pulmonary hypertension
Pulmonary hypertension has been deﬁned as a mean pulmonary
arterial pressure (PAPm) ≥25 mmHg. Normal PAPm values are 14
± 3 mmHg with an upper limit of normal (deﬁned as mean value +
2 SD) of 20 mmHg [5,6]. The “grey area” between 20 and 25 mmHg
at rest has yet to be suﬃciently deﬁned. The criterion of increase
in PAPm >30 mmHg on exercise that was valid until recently has
been abandoned, after a structured review of previously published
right heart catheterizations in healthy subjects demonstrated that
physiological pressure values on exercise can be much higher,
especially in elderly patients [5]. With the currently available data
it is not possible to specify a threshold above which an increase in
pulmonary pressure on exercise is pathological.
Comment:
The current hemodynamic deﬁnition of PH is basically oriented on
the previous treatment studies on PH which enrolled only patients with
a PAPm ≥25 mmHg. Data on PH associated with chronic lung disease
which indicated that lower mean pulmonary arterial values could also
be of clinical and prognostic signiﬁcance, was not taken into account
(see below). On the other hand, it is not yet clear if the treatment of
patients with mildly elevated pulmonary pressure values will provide a
clinical beneﬁt. Lower cut-off values would furthermore automatically
increase the number of patients who were incorrectly diagnosed with
PH or PAH. In view of these uncertainties, the current hemodynamic
deﬁnition of PH seems justiﬁed. Currently, this also applies to the
elimination of exercise cut-off values since, at present, it is not possible
to determine general cut-off values for pulmonary pressure on exercise
on the one hand, and, on the other hand, there is no evidence yet
that patients with normal pulmonary pressures at rest but “elevated”
pressures on exercise beneﬁt from pulmonary vasodilator therapy at
all.
Table 1
Updated clinical classiﬁcation of pulmonary hypertension (Dana Point, 2008).
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable PAH
1.2.1. BMPR2 mutations
1.2.2. ALK1, endoglin mutations (with and without hereditary
hemorrhagic telangiectasia)
1.2.3. Unknown mutations
1.3. Drugs or toxins induced
1.4. Associated with:
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart disease
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5. Persistent pulmonary hypertension of the newborn
1’. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary
hemangiomatosis (PCH)
2. Pulmonary hypertension due to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension due to lung diseases and/or hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive/obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation syndrome
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear or multifactorial mechanisms
5.1. Hematological disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders, sarcoidosis, pulmonary Langerhans cell
histiocytosis, lymphangioleiomyomatosis, neuroﬁbromatosis,
vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease,
thyroid disorders
5.4. Others: tumoral obstruction, ﬁbrosing mediastinitis, chronic renal
failure on hemodialysis
BMPR-2, bone morphogenetic protein receptor type-2; ALK-1, activin receptor-like
kinase 1 gene.
3. Pulmonary hypertension due to chronic lung disease:
prevalence and prognostic signiﬁcance
PH occurs frequently in patients with chronic obstructive lung
disease (COPD) as well as in patients with interstitial lung disease
(ILD); in some series the prevalence of PH was >50% [7,8]. In
the majority of these cases, PH was only mild and demonstrated
other characteristics than PAH, i.e. pulmonary pressures were less
elevated (mean pulmonary arterial pressures rarely exceeded 35
mmHg), cardiac output usually remained normal, and pulmonary
vascular resistance was only slightly to moderately increased (only
in exceptional cases >480 dyn s cm−5) [7,8]. However, there are
reports indicating that mild forms of PH in patients with chronic
lung disease may also be of prognostic signiﬁcance (see below).
Comment:
Information on the incidence of PH in patients with chronic lung
disease varies depending on the chosen deﬁnition of PH as well
as the investigated patient population and method of examination
(echocardiography versus right heart catheterization). A study by
the National Emphysema Treatment Trials (NETT) published in 2002,
showed that 90% of all patients with advanced pulmonary emphysema
who were evaluated for lung volume reduction (LVR) had a mean
pulmonary arterial pressure (PAPm) >20 mmHg and approx. 50%
had a PAPm >25 mmHg [9]. Another patient population with severe
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COPD that was evaluated for LVR or lung transplantation, also showed
PAPm values >25 mmHg in 50% of all cases [10]. Similar numbers
were published for patients with interstitial lung disease [11]. At
least in selected case series of patients who were evaluated for lung
transplantation due to advanced pulmonary ﬁbrosis, the prevalence of
PH with PAPm values >25 mmHg was between 30 and 70% [8,12,13].
No concrete information is available on the incidence of PH in
patients with less advanced lung disease since naturally these patients
are not systematically examined with right heart catheterization.
Echocardiographic examinations are not accurate enough to generate
epidemiological data (see below).
Irrespective of this, PH is less pronounced in most patients with
lung disease than in patients with “true” PAH and right ventricular
systolic pump failure does generally not occur. Nevertheless, there
are numerous studies indicating that even mild forms of PH may be
clinically signiﬁcant in patients with COPD as well as in patients with
pulmonary ﬁbrosis, since they are associated with worse oxygenation,
decreased exercise capacity, and poorer prognosis. Oswald-Mammoser
et al. were able to demonstrate that a PAPm >25 mmHg in COPD is
associated with increased mortality. In a study by Weitzenblum et al.,
the 4-year survival rate of COPD patients was 72% if the PAPm was
below 20 mmHg but only 49% with a PAPm >20 mmHg [14]. Similar
ﬁndings were established in patients with pulmonary ﬁbrosis [11]. A
prospective study with 87 patients with idiopathic pulmonary ﬁbrosis
published in 2007, a PAPm >17 mmHg was already linked to a poorer
prognosis [15]. At least 50% of all patients with combined pulmonary
ﬁbrosis and emphysema (CPFE) also have PH which likewise constitutes
an independent risk factor for increased mortality [16,17].
The most recent NETT data on PH in patients with pulmonary
emphysema was presented by Minai et al. in May 2010 during the
American Thoracic Society’s annual convention. 1,866 patients had
been enrolled making this series one of the largest in this patient
population. All patients underwent echocardiographic assessment;
systolic pulmonary arterial pressure (PA pressure) ≥45 mmHg was
determined as cut-off value. No further investigation was carried out
in patients with a systolic PA pressure <45 mmHg (n = 1,069; 57%),
while patients with a systolic PH pressure ≥45 mmHg underwent right
heart catheterization. This procedure conﬁrmed PH with a PAPm of
≥25 mmHg in 302 (38%) patients, which once more underlines the
insuﬃcient accuracy of determining PA pressure with echocardiography
(see below). Prespeciﬁed criteria for severe pulmonary hypertension
were (i) PAPm >35 mmHg, or (ii) PAPm ≥25 mmHg with a cardiac
index <2.0 l/min/m2, or (iii) pulmonary vascular resistance (PVR) >6
Wood units (corresponding to 480 dyn s cm−5). According to these
criteria, 18 (2.2%) patients had severe PH, including only one patient
with a PAPm >35 mmHg (Minai O et al. ATS 2010). Surprisingly, in
this population the presence of PH did not affect the survival rates after
1, 2 and 5 years (p = 0.19 for patients with a PAPm ≥25 mmHg versus
<25 mmHg).
The issue of which degree of PH can be expected within the context
of lung disease is of paramount importance, since in some cases the
lung disease may not be the only cause of PH so that further diagnostic
procedures are necessary to e.g. rule out causative heart disease, liver
disease, or CTEPH. In some cases it is even possible that the PH is a
“true” PAH with a coexisting lung disease and no causal signiﬁcance.
If a population has a high prevalence of a disease such as COPD, it
should be expected that it will also occur at a comparative prevalence
in patients with PAH.
Chaouat et al. were able to demonstrate that 27 out of 998 patients
with COPD and chronic respiratory failure who underwent right heart
catheterization had severe pulmonary hypertension, deﬁned as PAPm
≥40 mmHg. Besides the already known COPD, 16 of these 27 patients
had at least one other disease that may have caused PH [18]. In the
other patients (approx. 1% of the study population) it was unclear if the
severe PH was actually secondary to COPD or an independent disease,
in other words ultimately an idiopathic PAH.
Table 2
Criteria for the presence of severe pulmonary hypertension in patients with
chronic lung disease*.
At least 2 of the following criteria must be met:
1. Mean PA pressure (PAPm) >35 mmHg
2. PAPm ≥25 mmHg with limited cardiac output (CI <2.0 l/min/m2)
3. Pulmonary vascular resistance (PVR) >480 dyn s cm−5
*As a rule, these criteria only apply if other causes of PH (e.g. chronic
thromboembolic PH or left ventricular failure) have been excluded.
Thabut et al. assessed 215 patients with very advanced COPD
prior to scheduled LVR or lung transplantation with right heart
catheterization: PAPm values of >25 mmHg, >35 mmHg, and >45
mmHg were found in 50.2%, 9.8% and 3.7% of patients, respectively.
One problem of such kind of studies is that they are conducted
predominantly in selected patient populations with very advanced
lung disease. Therefore there is little reliable data on the prevalence
and degree of PH in patients with less severe forms of chronic lung
disease. The summarized data above from the NETT registry could
most likely be regarded as representative, not only because of the very
large number of cases but also because not only patients with severe
emphysema were enrolled.
The available data on patients with pulmonary ﬁbrosis is still un-
certain since almost all studies with invasive hemodynamics originated
from pre-transplantation populations and the patients had been pre-
selected accordingly. Larger-scale studies are almost exclusively based
on echocardiographic examinations with the corresponding limitations.
If pulmonary hypertension is more severe than expected, it is
always suspected that PH cannot be attributed to the pulmonary
disease alone. But what range can be expected? In the most recent
data from the NETT registry mentioned above, 38% of the examined
COPD patients suffered from pulmonary hypertension with a PAPm
≥25 mmHg, but only approx. 1% of all patients met the criteria for
severe PH (PAPm >35 mmHg or PAPm ≥25 mmHg with a cardiac
index < 2.0 l/min/m2, or PVR >480 dyn s cm−5) chosen for this study.
As opposed to previous studies on PH due to chronic lung disease, not
only the level of PA pressure was chosen as criterion for severity from
the NETT registry, but at the same time cardiac index and PVR were
used so that the impact of pulmonary hypertension on right ventricular
function was taken into account as well.
The German consensus group agreed to adopt the above-mentioned
deﬁnition of severe PH from the NETT registry in a modiﬁed, stricter
form (Table 2). Although this deﬁnition has been derived from patients
with COPD, it suﬃciently corresponds with the available ﬁndings from
patient populations with different interstitial lung diseases [19] to
be used by the consensus group for all other lung diseases as well.
This deﬁnition ensures that only hemodynamically relevant pulmonary
hypertension with distinct right ventricular load is classiﬁed as severe.
Since only a negligible minority of patients (<5%) with lung disease
presents such pronounced pulmonary hypertension, it satisﬁes the “out
of proportion” concept. At the time, this deﬁnition requires a complete
right heart catheterization including measurement of cardiac output
(see below).
4. Diagnosis of pulmonary hypertension due to chronic lung
disease
The diagnostic procedure in patients with suspected PH requires
a number of tests to conﬁrm the diagnosis, to determine the clinical
classiﬁcation of PH, and evaluate the severity of the functional as
well as the hemodynamic impairment. It is especially important to
fully clarify the diagnosis of patients with severe PH, since chronic
lung disease alone is generally not suﬃcient to cause severe PH
(see above). After the description of each procedure, an integrated
diagnostic algorithm of the guidelines is shown in Fig. 1.
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Fig. 1. Diagnostic algorithm. Explanation: TTE, transthoracic echocardiography; HRCT, high-resolution CT; V/Q scan, ventilation/perfusion lung scan; PAPm, mean pulmonary
arterial pressure; PCWP, pulmonary capillary wedge pressure; CTEPH, chronic thromboembolic pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; PCH,
pulmonary capillary hemangiomatosis; CTD, connective tissue disease; CHD, congenital heart disease; TEE, transesophageal echocardiography; CMRI, cardiac magnetic
resonance imaging; US, ultrasonography abdomen; ALK-1, activin-receptor-like kinase; BMPR2, bone morphogenetic protein receptor 2; HHT, hereditary hemorrhagic
telangiectasia (Osler’s disease)
4.1. Symptoms and clinical ﬁndings
The symptoms of PH are non-speciﬁc. This applies especially
to the main symptom, exercise dyspnea, which is naturally also
a key symptom of the underlying disease. Therefore the issue of
whether the extent of dyspnea can be explained by the level of
limited ventilatory function constitutes an important aspect of the
diagnostic clariﬁcation of such patients. Otherwise the presence of
PH should be taken into consideration.
The physical examination ﬁndings that may indicate PH include
visible and palpable left parasternal pulsations, an accentuated pul-
monary component of second heart sound, a left parasternal systolic
murmur of tricuspid regurgitation, and a diastolic murmur of pul-
monary valve insuﬃciency. Jugular vein distention, hepatomegaly,
peripheral edema, and ascites indicate severe PH. However, edema
may occur in chronic lung disease, especially in exacerbated chronic
obstructive pulmonary disease (COPD), even without the presence
of PH.
4.2. Electrocardiogram (ECG)
The ECG may provide evidence of PH in the presence of typical
signs (P-pulmonale, RV hypertension, depolarization disorder over
the anterior wall leads and inferior leads, right bundle branch
block). Signs of right ventricular load in the ECG of patients with
COPD are relevant for prognosis [20].
Sensitivity and speciﬁcity of the ECG to detect PH have not been
suﬃciently investigated in patients with chronic lung disease. Just
as in other forms of PH, absence of the above-mentioned signs of
right ventricular load by no means rule out the presence of PH.
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4.3. Radiology
Dilation of central pulmonary vessels (>15 mm for the right
lower lobe branch in the chest radiograph, >25 mm for the
pulmonary trunk in the CT scan) is regarded as an indication for
the presence of PH. The degree of PH does not correlate with the
radiological ﬁnding and normal radiographic ﬁndings do not rule
out PH.
4.4. Pulmonary function and blood gas analysis
The ﬁndings of spirometry and body plethysmography are
determined by the underlying lung disease and are not signiﬁcantly
affected by concomitant PH. Decreased lung diffusion capacity for
carbon monoxide (DLCO) and inadequate severe hypoxemia may
be possible indicators of PH. Patients with chronic hypercapnia
are at increased risk of PH. On the other hand, pronounced
hyperventilation can be an indicator of severe PH especially in
patients with chronic lung disease.
4.5. Echocardiography
Transthoracic echocardiography plays a central role in the initial
conﬁrmation of suspected PH. The estimation of PAP is based on
the Doppler-echocardiographic measurement of the peak velocity
of the tricuspid regurgitation jet (Vmax). The simpliﬁed Bernoulli
equation (P = 4 × Vmax2 ) is used to determine the pressure
gradient between right ventricle and right atrium. Right atrial
pressure is usually estimated based on the diameter and respiratory
variation of the inferior vena cava. This procedure, however, was
proven to be unreliable especially in patients with COPD. A Doppler
signal over the tricuspid valve can only be measured in 38–70%
of these patients [21–23]. In current studies, 50% of invasively
assessed systolic pulmonary arterial pressures deviated from the
values determined with echocardiography by more than 10 mmHg
[24,25]. Overestimated right arterial pressure values as well as
inadequate Doppler signals were identiﬁed as essential sources of
errors in echocardiography [25]. Studies with a Vmax cut-off value
of 2.5–2.8 m/s for PH at rest, had yielded false positive results in
45–72% of cases [24,26].
Indications for echocardiography to evaluate PH in patients
with COPD or interstitial lung disease include: (i) conﬁrmation or
exclusion of PH, (ii) clariﬁcation of concomitant left heart disease,
and (iii) the selection of patients for right heart catheterization
necessary for the conclusive diagnosis of PH.
Comment:
Despite its limitations, echocardiography in patients with chronic
lung disease remains the most important initial method of investigation
when PH is suspected. In the current NETT registry data, echocardiog-
raphy had a positive predictive value of 0.56 and a negative predictive
value of 0.82 (Minai et al. ATS 2010), whereby the cut-off value was set
at a systolic PA pressure of 45 mmHg. It is decisive that the examiner
is aware of the limitations of this procedure and interprets the ﬁndings
with the necessary prudence. As in other types of PH, the diagnosis
should, in principle, not be established on echocardiography alone,
especially if therapeutic consequences are being considered.
4.6. Ventilation/perfusion lung scan/V/Q scan)
The ventilation/perfusion lung scan is used to exclude or conﬁrm
chronic thromboembolic pulmonary hypertension (CTEPH).
Comment:
Sensitivity and speciﬁcity of the V/Q scan decrease with increasing
severity of obstructive or restrictive lung disease. If therapeutic con-
sequences can be expected, contrast-enhanced computed tomography
(CT) should be preferred in advanced lung disease.
4.7. Computed tomography of the chest
High-resolution CT (HR-CT) is an integral part of the diagnosis
of interstitial lung disease and pulmonary emphysema. In addition,
the CT can provide evidence of pulmonary hypertension (central
pulmonary vessels >25 mm) or right ventricular load.
4.8. Laboratory tests
The determination of the BNP or NTproBNP values can be
helpful within the scope of the initial diagnosis and for follow-
up assessments. However, elevated BNP/NTproBNP levels are not
speciﬁc for PH since increased values are also present in left
ventricular failure. Then again, normal BNP/NT-proBNP values do
not exclude PH [27].
4.9. Right heart catheterization and vasoreactivity test
Right heart catheterization (RHC) is required to conﬁrm the
diagnosis of PH and to assess its severity. The examination should
generally only be performed at centers that have extensive ex-
perience in the diagnosis and therapy of PH. When performed at
experienced centers, the rate of complications associated with this
examination is low (morbidity 1.1%, mortality 0.055%) [28].
Indications for right heart catheterization in patients with
chronic lung disease may include: (i) conﬁrmation of diagnosis or
exclusion of PH in patients prior to surgical interventions (trans-
plantation, LVR), (ii) suspected out of proportion PH, (iii) repeated
episodes of right ventricular failure, (iv) uncertain echocardio-
graphic ﬁndings with coexisting clinical indications of PH.
The following parameters must be determined with each right
heart catheterization: right atrial pressure, pulmonary arterial pres-
sure, pulmonary capillary wedge pressure (if technically feasible),
cardiac output (thermodilution or Fick method with measured
oxygen consumption, tabular oxygen consumption is not reliable
enough), as well as mixed venous oxygen saturation.
Comment:
The recommendations for right heart catheterization in patients
with chronic lung disease sometimes lead to misunderstandings. On no
account do the guidelines require RHC in all patients with chronic lung
disease and clinical signs of PH. This type of intervention is only deemed
necessary if therapeutic consequences are expected or if important
prognostic information is needed for continued patient management
(e.g. placing on the lung transplant list). Since the European guidelines
generally do not recommend targeted drug therapy of PH in patients
with chronic lung disease, RHC will only be necessary in exceptional
cases (see below).
RHC should only be performed at locations where the above-
mentioned hemodynamic parameters can be fully collected, otherwise
the patients should be referred to appropriate centers.
Vasoreactivity testing should be considered in patients with PH due
to chronic lung disease.
The signiﬁcance of exercise hemodynamics during right heart
catheterization is currently not established.
5. Treatment of pulmonary hypertension due to chronic lung
disease
At present there is no speciﬁc treatment for PH due to chronic
lung disease. Long-term oxygen treatment (LTOT) reduces progres-
sion in PH due to COPD. Only in rare cases does this treatment
lead to the normalization of pulmonary pressures and the structural
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Table 3
Recommendations of the European guidelines for pulmonary hypertension
associated with lung disease and/or hypoxia.
Recommendation Class of recom-
mendation
Level of
evidence
Echocardiography is a recommended screening
method for PH due to lung disease
I C
In patients with PH due to lung disease, RHC
is recommended to conﬁrm diagnosis
I C
The optimization of treatment of patients with
PH due to lung disease including long-term
oxygen therapy for hypoxemia is
recommended
I C
Patients with out or proportion PH due to
lung disease should be enrolled in RCTs for
PAH-targeted drugs
IIa C
The treatment of patients with PH due to lung
disease with PAH-targeted drugs is not
recommended
III C
PH, pulmonary hypertension; RCTs, randomized controlled trials; PAH, pulmonary
arterial hypertension; RHC, right heart catheterization.
changes of lung vessels are not affected [29]. The role of LTOT for
the progression of PH in interstitial lung disease is even less well
established.
The treatment of PH due to chronic lung disease with conven-
tional vasodilators (e.g. calcium channel blockers) is not recom-
mended, since the inhibition of hypoxic vasoconstriction can lead to
worsening of gas exchange and these agents provide no long-term
beneﬁt [30–34]. The available data on the use of “PAH drugs”,
in other words prostanoids, endothelin receptor antagonists, and
phosphodiesterase type-5 inhibitors [35–37], in these patients is
insuﬃcient and limited to a few studies on acute effects as well as
uncontrolled studies with only few case numbers.
The treatment of choice for hypoxemic patients with COPD or
interstitial lung disease and concomitant PH is LTOT. Patients with
“out of proportion” PH (characterized by the fact that the extent
of dyspnea can not be explained by the lung disease alone and a
PAPm >40 mmHg at rest) should be referred to expert centers and
enrolled in clinical studies. The use of “PAH drugs” is not advised
in these patients since systematic studies on safety and eﬃcacy are
not available. The recommendations of the European guidelines on
PH due to chronic lung disease are summarized in Table 3. The
deﬁnitions for the class of recommendations or levels of evidence
correspond to the tables in the preamble of this brochure.
Comment:
Some treatment principles for patients with chronic lung disease
and PH are undisputable even if there is only little reliable data to
this end. For instance, this applies to long-term oxygen treatment
for patients with chronic hypoxemia regardless of the underlying lung
disease, even if corresponding reliable data is only available for patients
with COPD.
The obstructive sleep apnea syndrome generally does not lead to
clinically relevant PH, a fact that must be considered when clarifying
the causes as well as in the treatment of PH or PAH. By contrast,
the presence of chronic hypercapnia associated with hypoventilation
syndromes of various origins can lead to severe PH. This is particularly
common in patients with kyphoscoliosis and in patients with obesity
hypoventilation syndrome. In these cases, causal treatment, usually
with non-invasive ventilation, is top priority especially since PH can
regress in these cases with eﬃcient treatment and normalization of
paCO2 values.
In the presence of PH and central sleep apnea, PH should not be
automatically classiﬁed as a result of sleep apnea. As in left ventricular
failure, severe PH also favors the occurrence of central sleep apnea [38].
There is insuﬃcient data on the issues of if and when patients
with chronic lung disease and pulmonary hypertension should receive
anticoagulation. This must currently be decided on an individual basis
only.
Use of “PAH drugs” in chronic lung disease
Up to now, no solid data is available on drug therapy for PH
in the context of chronic lung disease. This applies to COPD as
well as to pulmonary ﬁbrosis and mixed forms. A small placebo
controlled study with the endothelin receptor antagonist bosentan in
patients with COPD without severe pulmonary hypertension showed
no improvement in exercise capacity but worsening of oxygenation
[39]. Acute data is available on the use of sildenaﬁl in patients with
COPD and PH which also demonstrates worsening of gas exchange with
simultaneous improvement of hemodynamic parameters [40]. There
is, however, no reliable long-term data on safety and tolerability for
sildenaﬁl in this patient group.
The recently published STEP-IPF study was not able to demonstrate
an improvement in exercise capacity in patients with IPF on a 12-week
therapy with sildenaﬁl but showed signiﬁcant albeit minor beneﬁts
with regard to oxygenation, DLCO, as well as dyspnea and quality
of life scores as compared to the placebo group. In these studies the
presence of PH was not required for study enrollment, but rather a
DLco <35% of the predicted value was used as inclusion criterion,
intending an enrichment of the study population with patients with
IPF-associated PH [41].
In view of this data, the working group agrees with the recom-
mendations of the guidelines not to systematically treat patients with
lung disease and PH with PAH drugs as long as there is no solid
corresponding data. This applies irrespective of the underlying lung
disease.
However, patients with lung disease and severe pulmonary hy-
pertension must be viewed separately, especially if the lung disease
has not progressed enough to be regarded as the sole cause of PH.
The guidelines refer to these cases as “out of proportion PH” without
clearly deﬁning this term. Because of the above-mentioned reasons, the
German consensus conference has decided to adopt the deﬁnition in
the NETT registry of severe PH due to chronic lung disease in modiﬁed
form (Table 2).
Patients with chronic lung disease have not been systematically
assessed in clinical studies with PAH drugs, so that there is no suﬃcient
evidence on the safety and beneﬁt of these drugs in these patient
groups. Some of these patients show clinical characteristics that apply
more to PH than to their lung disease [18]. In such borderline cases
it may be diﬃcult or even impossible to differentiate if a patient is
suffering from chronic lung disease with resulting PH or from PAH with
concomitant but not causative chronic lung disease. In the latter case
it would not be justiﬁable to deny a patient targeted PAH therapy.
Such patients should be enrolled in clinical studies in accordance with
the recommendations of the European guidelines. Several Phase II and
Phase III studies are currently under way but the majority of patients
will not meet the inclusion and exclusion criteria. This option can,
therefore, not be considered in general. The decision regarding targeted
therapy will then fall within the discretion of the treating physician.
The following constellation of ﬁndings indicates that patients who
suffer from chronic lung disease also have severe PH, whereby it is
not always possible to clearly differentiate between PH within the
scope of the underlying disease and PAH: Mild to moderate severity
of ventilatory limitation, i.e. total lung capacity (TLC) in pulmonary
ﬁbrosis > approx. 60% of the predicted value, in COPD FEV1 > ca.
50% of the predicted value, hyperventilation or at least absence of
hypercapnia and coexistence of severe PH corresponding to the criteria
in Table 2 which cannot be explained by a further disease (e.g. left
ventricular failure, pulmonary embolism).
These hemodynamic values should not be measured immediately
after exacerbation of the underlying disease (if applicable at an interval
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of ≥6 weeks). Furthermore, these patients should be screened for
other causes of PH in accordance with the above diagnostic algorithm
(Fig. 1).
Recommendations of the working group
General remarks
With regard to these cut-off values and the potential consequences
for the medical treatment of patients with chronic lung disease, this
consensus document differs from the European guidelines.
• In the majority of cases, the pathology and pathophysiology PH in
chronic lung diseases is clearly different from PAH. In individual
cases, especially in the presence of severe pulmonary hypertension,
there are pathological and pathophysiological similarities between
PAH and severe PH due to chronic lung disease.
• It is conceivable that in individual cases, lung disease could “trigger”
the development of PAH (analog to other diseases such as collagen
vascular disease, HIV infection, or portal hypertension).
• In patients with mild to moderately severe ventilation disorder
but concomitant severe increased pulmonary pressure, PH may
dominate the clinical symptoms. In some cases, it is almost
impossible to distinguish the clinical symptoms from PAH.
• Some studies on PAH drugs have enrolled patients with mild
to moderate obstructive and restrictive ventilation disorders in
accordance with the above criteria (TLC >60% of the target value,
FEV1 >50% of the target value).
• There is limited clinical experience on the use of “PAH drugs”
in patients with chronic lung disease. Since these patients are
suffering from life-threatening illnesses, there is a medical-ethics
dilemma between the availability of evidence-based data and the
vital need for treatment. This is all the more true since it will hardly
be possible to generate suﬃcient data for all conceivable chronic
lung diseases with concomitant PH that meet the requirements of
evidence-based medicine. In such cases, the essential task of the
physician consists of applying the best possible treatment for the
patient taking into consideration beneﬁts, risks, and costs.
Speciﬁc recommendations of the working group on the treatment
of PH in patients with chronic lung disease
• The targeted treatment with “PAH drugs” is generally not rec-
ommended and should be reserved for exceptional cases. The
treatment decisions in these cases should be made only at expert
centers (deﬁnition according to the European guidelines, Table 4).
• Use of such treatment requires comprehensive diagnostic proce-
dures according to the recommendations of the guidelines, including
right heart catheterization. The patients should meet the following
criteria: (i) invasive assessment of severe PH according to the
criteria in Table 2, (ii) mild to moderate severity of ventilatory
limitation as deﬁned above, (iii) exclusion of other causes of PH,
including left heart disease and CTEPH.
• Before these patients are treated with “PAH drug”, it should be
assessed if they are eligible for a clinical study. Large PH centers as
well as PH self-help groups (pheV) will provide information about
this.
• Even if the patients thus characterized are potentially suffering from
PAH, they have so far not been systematically enrolled in clinical
studies due to their limited pulmonary function. Accordingly, the
safety as well as the eﬃcacy of “PAH drugs” is not suﬃciently char-
acterized in such cases so that patients should be closely monitored.
This includes controls of arterial or capillary blood gases.
• Because of the limited available scientiﬁc data, no recommendations
can be made about which substance group should be preferred.
• Unlike in PAH, it not yet known if the “PAH drugs” have a positive
effect on disease progression in patients with chronic lung disease
and PH. Hence, a treatment attempt should initially be made over a
limited period of 3–6 months in order to decide then, after careful
Table 4
Deﬁnition of a pulmonary hypertension referral center.
Recommendation Class of recom-
mendation
Level of
evidence
A pulmonary hypertension referral center
must provide a professional, interdisciplinary
team (cardiologists, respiratory medicine
physicians, clinical nurse specialists,
radiologists, psychologists, social work
support, appropriate on-call expertise in PH)
I C
Pulmonary hypertension referral centers are
required to have direct lines and quick referral
patterns to other departments, experts, and
programs (rheumatology centers, family
planning service, PEA program, lung
transplantation service, center for adult
patients with congenital heart disease)
I C
A pulmonary hypertension referral center
should follow at least 50 patients with PAH or
CTEPH and should treat at least two new
patients per month with documented PAH or
CTEPH.
IIa C
Pulmonary hypertension referral centers
should perform at least 20 vasoreactivity tests
in patients with PAH per year.
IIa C
Pulmonary hypertension referral centers
should participate in clinical research in PAH
(including Phase II and III studies)
III C
CT, computed tomography; CTEPH, chronic thromboembolic pulmonary
hypertension; PAH, pulmonary arterial hypertension, PH, pulmonary hypertension;
PAP, pulmonary arterial pressure; PEA, pulmonary endarterectomy.
re-evaluation, if an objective clinical effect has occurred that would
justify the continuation of therapy. Otherwise the treatment should
be discontinued. This approach should be discussed with the patient
before the start of treatment.
• A special situation arises if patients have end-stage lung disease
and are on a lung transplant waiting list. Here, the treatment
of severe pulmonary hypertension is justiﬁed in individual cases
under clinically controlled conditions with the foreseeable goal of
reaching transplantation, especially if a clinical improvement can
be documented on this treatment.
Closing remarks
The recommendations of the Cologne Consensus Conference differ
in some parts from the current European guidelines, especially with
regard to the treatment of PH due to chronic lung disease. Large parts
of the European guidelines are strictly evidence-based. The consensus
conference adopted these guidelines in essence but at the same time
attempted to make recommendation for patients presenting in a grey
zone where it is very diﬃcult to distinguish between PH due to chronic
lung disease and PAH. This is a diﬃcult and sometimes unsatisfying
endeavor, since on the one hand the uncritical and unjustiﬁed use
of “PAH drugs” should be avoided but on the other hand it must be
prevented that patients do not receive these drugs for formal reasons
even though experienced physicians see a realistic chance that patients
may beneﬁt from them.
The members of this working group have observed with great
unease that “PAH drugs” are increasingly used by non-experts and
oftentimes for patients for whom these drugs are not indicated or the
indication has not been carefully assessed. In many of these cases, the
treating physicians do not seem to understand the difference between
PAH and other forms of PH. This development may have negative
consequences: Those patients not suffering from PAH may be treated
with drugs they will not beneﬁt from while patients with established
PH are denied comprehensive and competent treatment at specialized
centers. In addition, the unjustiﬁed use of “PAH drugs” results is an
economic burden to the health care system.
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Only carefully designed clinical trials and registries will help to
further elucidate which patients may beneﬁt for “PAH drugs”, and
which not. Until more data is available, the best way to avoid over-,
under- and mistreatment of patients with PH and chronic lung disease
is referring them to expert centers, as recommended by the European
guidelines.
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